Financial Summary

Takeda Pharmaceutical Company Limited  (TAK)  $16.71    (%)

  • Symbol
    TAK
    Price
    16.71$
    Beta
    1.110217
    Volume Avrg.
    3580309
    Market Cap
    53074297000
    Last Div
    0.419053
    Range
    12.43-20.0
    Changes
    -0.04
    Changes Percentage
    Exchange
    NYSE
    Industry
    Drug Manufacturers General Specialty & Generic
    Ceo
    Mr. Christophe Weber
    Sector
    Healthcare

About company

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a corporate strategic research alliance with Egle Therapeutics SAS; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.


Income Statement

Year Revenue Cost of revenues Gross profit Operating expensess Operating incomes Interest expense Income tax expenses Earnings before taxs Net income Earnings per share basics Earnings per share diluteds Dividend per shares Gross margins EBIT margins Profit margins EBITDA EBIT Earnings Before Tax Margins Net Profit Margins
2020 274515.00 169559.00 104956.00 38668.00 66288.00 0.00 968.00 67091.00 57411.00 3.31 3.28 0.803333414346 0.382332477278109 0.300289471658 0.209136112780722 77344.00 66288.00 0.244398302460703 0.209136112780722
2019 260174.00 161782.00 98392.00 34462.00 6393.00 3576.00 10481.00 65737.00 55256.00 2.97145 2.97145 3.03705403822 0.378178 0.245720171885 0.212381 8186.00 6393.00 0.252666 0.212381
2018 265595.00 163756.00 101839.00 30941.00 70898.00 324.00 11872.00 72903.00 59531.00 2.97649 2.97649 2.74234021698 0.383437 0.266940266195 0.224142 85546.00 70898.00 0.274489 0.224142
2017 229234.00 141048.00 88186.00 26842.00 61344.00 2323.00 15738.00 64089.00 48351.00 2.3175 2.3025 2.43140686849 0.384698604918991 0.267604282087 0.210924208450753 76569.00 61344.00 0.27957894553164 0.210924208450753
2016 215639.00 131376.00 84263.00 24239.00 60024.00 1456.00 15685.00 61372.00 45687.00 2.07658 2.07658 2.20897805039 0.39076 0.278354101067 0.211868 73333.00 60024.00 0.284605 0.211868
2015 233715.00 140089.00 93626.00 22396.00 7123.00 733.00 19121.00 72515.00 53394.00 2.30422 2.30422 1.99566067658 0.400599 0.304772907173 0.228458 84505.00 7123.00 0.310271 0.228458
2014 182795.00 112258.00 70537.00 18034.00 52503.00 384.00 13973.00 53483.00 3951.00 1.61318 1.61318 1.817183144 0.38588 0.287223392325 0.216144 61813.00 52503.00 0.292585 0.216144
2013 17091.00 106606.00 64304.00 15305.00 48999.00 136.00 13118.00 50155.00 37037.00 1.41969 1.41969 11.338876116 0.376245 0.286694751624 0.216705 57048.00 48999.00 0.293459 0.216705
2012 156508.00 87846.00 68662.00 13421.00 55241.00 1088.00 1403.00 55763.00 41733.00 1.57673 1.57673 2.63181556135 0.438712 0.35295959312 0.266651 60128.00 55241.00 0.356295 0.266651
2011 108249.00 64431.00 43818.00 10028.00 3379.00 519.00 8283.00 34205.00 25922.00 0.98833 0.98833 0.0 0.404789 0.312150689614 0.239466 36538.00 3379.00 0.315984 0.239466
2010 65225.00 39541.00 25684.00 7299.00 18385.00 311.00 4527.00 1854.00 14013.00 0.54121 0.54121 0.0 0.393775 0.281870448448 0.214841 19878.00 18385.00 0.284247 0.214841
2009 42905.00 25683.00 17222.00 5482.00 1174.00 407.00 3831.00 12066.00 8235.00 0.32426 0.32426 0.0 0.401398 0.2812 0.191936 13207.00 12066.00 0.281226 0.191936
Year202020192018201720162015201420132012201120102009
Revenue274515.00260174.00265595.00229234.00215639.00233715.00182795.0017091.00156508.00108249.0065225.0042905.00
Cost of revenues169559.00161782.00163756.00141048.00131376.00140089.00112258.00106606.0087846.0064431.0039541.0025683.00
Gross profit 104956.00 98392.00 101839.00 88186.00 84263.00 93626.00 70537.00 64304.00 68662.00 43818.00 25684.00 17222.00
Operating expensess38668.0034462.0030941.0026842.0024239.0022396.0018034.0015305.0013421.0010028.007299.005482.00
Operating incomes66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.001174.00
Interest expense0.003576.00324.002323.001456.00733.00384.00136.001088.00519.00311.00407.00
Income tax expenses968.0010481.0011872.0015738.0015685.0019121.0013973.0013118.001403.008283.004527.003831.00
Earnings before taxs67091.0065737.0072903.0064089.0061372.0072515.0053483.0050155.0055763.0034205.001854.0012066.00
Net income57411.0055256.0059531.0048351.0045687.0053394.003951.0037037.0041733.0025922.0014013.008235.00
Earnings per share basics3.312.971452.976492.31752.076582.304221.613181.419691.576730.988330.541210.32426
Earnings per share diluteds3.282.971452.976492.30252.076582.304221.613181.419691.576730.988330.541210.32426
Dividend per shares0.83.042.742.432.2121.8211.342.63000
Gross margins0.380.380.380.380.390.40.390.380.440.40.390.4
EBIT margins0.30.250.270.270.280.30.290.290.350.310.280.28
Profit margins0.210.210.220.210.210.230.220.220.270.240.210.19
EBITDA77344.008186.0085546.0076569.0073333.0084505.0061813.0057048.0060128.0036538.0019878.0013207.00
EBIT66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.0012066.00
Earnings Before Tax Margins0.240.250.270.280.280.310.290.290.360.320.280.28
Net Profit Margins0.210.210.220.210.210.230.220.220.270.240.210.19